Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the ...

The bank noted that Phase 1 testing for CRB-913 was expected to begin in Q1, with data in the second half of 2025. Piper set a price target for Corbus of $35.For Viking (), Piper cited the company ...

Corbus Pharmaceuticals on Friday presented new data from the first Western study of its antibody-drug conjugate treatment for cancer that largely mirrored previous results reported from China ...

Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe’s reaction to talk of an academic brain drain in the U.S., and more. Moderna missed earnings forecasts ...

Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day moving average price is $20.82.

Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...